Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (327)	10/8/1999 8:40:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1169

apologies if this has been posted previously...... Australas J Dermatol 1999 Aug;40(3):135-7 Widespread plaque psoriasis responsive to mycophenolate mofetil. Tong DW, Walder BK Department of Dermatology, Prince of Wales Hospital, Randwick, New South Wales, Australia. A woman with a long history of widespread plaque psoriasis unresponsive to and/or intolerant of phototherapy, retinoids, methotrexate and cyclosporin was successfully treated with mycophenolate mofetil. Remission was maintained on doses between 1 and 1.5 g/day for 18 months without adverse effects.